Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 198 entries
Sorted by: Best Match Show Resources per page
Prevalence of Type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multi-center study in Brazil.

The review of diabetic studies : RDS

Gomes MB, Gianella D, Faria M, Tambascia M, Fonseca RM, Réa R, Macedo G, Modesto Filho J, Schmid H, Bittencourt AV, Cavalcanti S, Rassi N, Pedrosa H, Atala Dib S.
PMID: 17487331
Rev Diabet Stud. 2006;3(2):82-7. doi: 10.1900/RDS.2006.3.82. Epub 2006 Aug 10.

Major clinical studies have shown that the targets for blood glucose, lipid profile and blood pressure in type 2 diabetic patients are difficult to maintain in clinical practice. However, there are few data concerning South American populations. Using guidelines...

Cite
Gomes MB, Gianella D, Faria M, et al. Prevalence of Type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multi-center study in Brazil. Rev Diabet Stud. 2006;3(2):82-7doi: 10.1900/RDS.2006.3.82.
Gomes, M. B., Gianella, D., Faria, M., Tambascia, M., Fonseca, R. M., Réa, R., Macedo, G., Modesto Filho, J., Schmid, H., Bittencourt, A. V., Cavalcanti, S., Rassi, N., Pedrosa, H., & Atala Dib, S. (2006). Prevalence of Type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multi-center study in Brazil. The review of diabetic studies : RDS, 3(2), 82-7. https://doi.org/10.1900/RDS.2006.3.82
Gomes, Marilia de Brito, et al. "Prevalence of Type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multi-center study in Brazil." The review of diabetic studies : RDS vol. 3,2 (2006): 82-7. doi: https://doi.org/10.1900/RDS.2006.3.82
Gomes MB, Gianella D, Faria M, Tambascia M, Fonseca RM, Réa R, Macedo G, Modesto Filho J, Schmid H, Bittencourt AV, Cavalcanti S, Rassi N, Pedrosa H, Atala Dib S. Prevalence of Type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multi-center study in Brazil. Rev Diabet Stud. 2006;3(2):82-7. doi: 10.1900/RDS.2006.3.82. Epub 2006 Aug 10. PMID: 17487331; PMCID: PMC1783582.
Copy Download .nbib Format: NLM
Prolactinoma in a diabetic dialysis patient with erectile dysfunction: a difficult differential diagnosis.

The review of diabetic studies : RDS

Piccoli GB, Bermont F, Magnano A, Soragna G, Terzolo M.
PMID: 17487344
Rev Diabet Stud. 2006;3(4):200-4. doi: 10.1900/RDS.2006.3.200. Epub 2007 Feb 10.

Dialysis patients often suffer from erectile dysfunction. The prevalence of this symptom in the context of dialysis is as high as 90%. Diabetes, diffuse vascular disease and pharmacological therapy are attendant causes of this condition, severely impairing the quality...

Cite
Piccoli GB, Bermont F, Magnano A, et al. Prolactinoma in a diabetic dialysis patient with erectile dysfunction: a difficult differential diagnosis. Rev Diabet Stud. 2007;3(4):200-4doi: 10.1900/RDS.2006.3.200.
Piccoli, G. B., Bermont, F., Magnano, A., Soragna, G., & Terzolo, M. (2006). Prolactinoma in a diabetic dialysis patient with erectile dysfunction: a difficult differential diagnosis. The review of diabetic studies : RDS, 3(4), 200-4. https://doi.org/10.1900/RDS.2006.3.200
Piccoli, Giorgina B, et al. "Prolactinoma in a diabetic dialysis patient with erectile dysfunction: a difficult differential diagnosis." The review of diabetic studies : RDS vol. 3,4 (2006): 200-4. doi: https://doi.org/10.1900/RDS.2006.3.200
Piccoli GB, Bermont F, Magnano A, Soragna G, Terzolo M. Prolactinoma in a diabetic dialysis patient with erectile dysfunction: a difficult differential diagnosis. Rev Diabet Stud. 2006;3(4):200-4. doi: 10.1900/RDS.2006.3.200. Epub 2007 Feb 10. PMID: 17487344; PMCID: PMC1828284.
Copy Download .nbib Format: NLM
The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.

The review of diabetic studies : RDS

Gallwitz B.
PMID: 17487346
Rev Diabet Stud. 2006;3(4):208-16. doi: 10.1900/RDS.2006.3.208. Epub 2007 Feb 10.

This article gives an overview of two recent trials investigating rosiglitazone, a thiazolidinedione, in its potential to prevent type 2 diabetes (T2D) and in its effectiveness in monotherapy. Thiazolidinediones are among the most important developments of recent years for...

Cite
Gallwitz B. The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions. Rev Diabet Stud. 2007;3(4):208-16doi: 10.1900/RDS.2006.3.208.
Gallwitz, B. (2006). The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions. The review of diabetic studies : RDS, 3(4), 208-16. https://doi.org/10.1900/RDS.2006.3.208
Gallwitz, Baptist. "The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions." The review of diabetic studies : RDS vol. 3,4 (2006): 208-16. doi: https://doi.org/10.1900/RDS.2006.3.208
Gallwitz B. The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions. Rev Diabet Stud. 2006;3(4):208-16. doi: 10.1900/RDS.2006.3.208. Epub 2007 Feb 10. PMID: 17487346; PMCID: PMC1828283.
Copy Download .nbib Format: NLM
Bilirubin increases the expression of glucose transporter-1 and the rate of glucose uptake in vascular endothelial cells.

The review of diabetic studies : RDS

Cohen G, Livovsky DM, Kapitulnik J, Sasson S.
PMID: 17487336
Rev Diabet Stud. 2006;3(3):127-33. doi: 10.1900/RDS.2006.3.127. Epub 2006 Nov 10.

BACKGROUND AND OBJECTIVES: The close contact between the endothelial cell monolayer in blood vessels and blood plasma allows free diffusion of the hydrophobic unconjugated bilirubin (BR) into these cells. BR can exert both anti- and pro-oxidative effects in various...

Cite
Cohen G, Livovsky DM, Kapitulnik J, et al. Bilirubin increases the expression of glucose transporter-1 and the rate of glucose uptake in vascular endothelial cells. Rev Diabet Stud. 2006;3(3):127-33doi: 10.1900/RDS.2006.3.127.
Cohen, G., Livovsky, D. M., Kapitulnik, J., & Sasson, S. (2006). Bilirubin increases the expression of glucose transporter-1 and the rate of glucose uptake in vascular endothelial cells. The review of diabetic studies : RDS, 3(3), 127-33. https://doi.org/10.1900/RDS.2006.3.127
Cohen, Guy, et al. "Bilirubin increases the expression of glucose transporter-1 and the rate of glucose uptake in vascular endothelial cells." The review of diabetic studies : RDS vol. 3,3 (2006): 127-33. doi: https://doi.org/10.1900/RDS.2006.3.127
Cohen G, Livovsky DM, Kapitulnik J, Sasson S. Bilirubin increases the expression of glucose transporter-1 and the rate of glucose uptake in vascular endothelial cells. Rev Diabet Stud. 2006;3(3):127-33. doi: 10.1900/RDS.2006.3.127. Epub 2006 Nov 10. PMID: 17487336; PMCID: PMC1783585.
Copy Download .nbib Format: NLM
Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action.

The review of diabetic studies : RDS

Durant S, Coulaud J, Homo-Delarche F.
PMID: 18084676
Rev Diabet Stud. 2007;4(3):185-94. doi: 10.1900/RDS.2007.4.185. Epub 2007 Nov 10.

The effects of bromocriptine (10 mg/kg), known to inhibit prolactin secretion and lower autoimmune processes, were studied on glucose homeostasis in non-fasted non-obese diabetic mice, a spontaneous model of type 1 diabetes. Hyperglycemia was observed 120 and 240 min...

Cite
Durant S, Coulaud J, Homo-Delarche F. Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action. Rev Diabet Stud. 2007;4(3):185-94doi: 10.1900/RDS.2007.4.185.
Durant, S., Coulaud, J., & Homo-Delarche, F. (2007). Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action. The review of diabetic studies : RDS, 4(3), 185-94. https://doi.org/10.1900/RDS.2007.4.185
Durant, Sylvie, et al. "Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action." The review of diabetic studies : RDS vol. 4,3 (2007): 185-94. doi: https://doi.org/10.1900/RDS.2007.4.185
Durant S, Coulaud J, Homo-Delarche F. Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action. Rev Diabet Stud. 2007;4(3):185-94. doi: 10.1900/RDS.2007.4.185. Epub 2007 Nov 10. PMID: 18084676; PMCID: PMC2174061.
Copy Download .nbib Format: NLM
DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety.

The review of diabetic studies : RDS

de Valk HW.
PMID: 18084670
Rev Diabet Stud. 2007;4(3):126-33. doi: 10.1900/RDS.2007.4.126. Epub 2007 Nov 10.

The incretin system has proven to be a new source of glucose-lowering drugs. Glucon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are the incretins which are degraded by dipeptidyl peptidase-4 (DPP-4). GLP-1 is the major relevant incretin in type...

Cite
de Valk HW. DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety. Rev Diabet Stud. 2007;4(3):126-33doi: 10.1900/RDS.2007.4.126.
de Valk, H. W. (2007). DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety. The review of diabetic studies : RDS, 4(3), 126-33. https://doi.org/10.1900/RDS.2007.4.126
de Valk, Harold W. "DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety." The review of diabetic studies : RDS vol. 4,3 (2007): 126-33. doi: https://doi.org/10.1900/RDS.2007.4.126
de Valk HW. DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety. Rev Diabet Stud. 2007;4(3):126-33. doi: 10.1900/RDS.2007.4.126. Epub 2007 Nov 10. PMID: 18084670; PMCID: PMC2174059.
Copy Download .nbib Format: NLM
Diabetes and impaired glucose regulation in first-degree relatives of patients with type 2 diabetes in isfahan, iran: prevalence and risk factors.

The review of diabetic studies : RDS

Amini M, Janghorbani M.
PMID: 18084674
Rev Diabet Stud. 2007;4(3):169-76. doi: 10.1900/RDS.2007.4.169. Epub 2007 Nov 10.

OBJECTIVES: The aim of this study was to estimate the prevalence of diabetes, impaired glucose tolerance (IGT), and impaired fasting glucose (IFG) in first-degree relatives (FDR) of people with type 2 diabetes mellitus.METHODS: A cross-sectional study of FDR of...

Cite
Amini M, Janghorbani M. Diabetes and impaired glucose regulation in first-degree relatives of patients with type 2 diabetes in isfahan, iran: prevalence and risk factors. Rev Diabet Stud. 2007;4(3):169-76doi: 10.1900/RDS.2007.4.169.
Amini, M., & Janghorbani, M. (2007). Diabetes and impaired glucose regulation in first-degree relatives of patients with type 2 diabetes in isfahan, iran: prevalence and risk factors. The review of diabetic studies : RDS, 4(3), 169-76. https://doi.org/10.1900/RDS.2007.4.169
Amini, Masoud, and Janghorbani, Mohsen. "Diabetes and impaired glucose regulation in first-degree relatives of patients with type 2 diabetes in isfahan, iran: prevalence and risk factors." The review of diabetic studies : RDS vol. 4,3 (2007): 169-76. doi: https://doi.org/10.1900/RDS.2007.4.169
Amini M, Janghorbani M. Diabetes and impaired glucose regulation in first-degree relatives of patients with type 2 diabetes in isfahan, iran: prevalence and risk factors. Rev Diabet Stud. 2007;4(3):169-76. doi: 10.1900/RDS.2007.4.169. Epub 2007 Nov 10. PMID: 18084674; PMCID: PMC2174064.
Copy Download .nbib Format: NLM
Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West.

The review of diabetic studies : RDS

Ikegami H, Noso S, Babaya N, Hiromine Y, Kawabata Y.
PMID: 18795209
Rev Diabet Stud. 2008;5(2):64-72. doi: 10.1900/RDS.2008.5.64. Epub 2008 Aug 10.

Type 1 diabetes is a multifactorial disease caused by a complex interaction of genetic and environmental factors. The genetic factors involved consist of multiple susceptibility genes, at least five of which, HLA, INS, CTLA4, PTPN22 and IL2RA/CD25, have been...

Cite
Ikegami H, Noso S, Babaya N, et al. Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West. Rev Diabet Stud. 2008;5(2):64-72doi: 10.1900/RDS.2008.5.64.
Ikegami, H., Noso, S., Babaya, N., Hiromine, Y., & Kawabata, Y. (2008). Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West. The review of diabetic studies : RDS, 5(2), 64-72. https://doi.org/10.1900/RDS.2008.5.64
Ikegami, Hiroshi, et al. "Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West." The review of diabetic studies : RDS vol. 5,2 (2008): 64-72. doi: https://doi.org/10.1900/RDS.2008.5.64
Ikegami H, Noso S, Babaya N, Hiromine Y, Kawabata Y. Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West. Rev Diabet Stud. 2008;5(2):64-72. doi: 10.1900/RDS.2008.5.64. Epub 2008 Aug 10. PMID: 18795209; PMCID: PMC2556443.
Copy Download .nbib Format: NLM
Endoplasmic reticulum stress caused by overexpression of islet-specific glucose-6-phosphatase catalytic subunit-related protein in pancreatic Beta-cells.

The review of diabetic studies : RDS

Shameli A, Yamanouchi J, Thiessen S, Santamaria P.
PMID: 17565413
Rev Diabet Stud. 2007;4(1):25-32. doi: 10.1900/RDS.2007.4.25. Epub 2007 May 10.

The high rate of protein synthesis in beta-cells renders them susceptible to endoplasmic reticulum (ER) stress, a condition that can be aggravated by additional imbalances in ER homeostasis and could potentially contribute to the pathogenesis of type-1 and type-2...

Cite
Shameli A, Yamanouchi J, Thiessen S, et al. Endoplasmic reticulum stress caused by overexpression of islet-specific glucose-6-phosphatase catalytic subunit-related protein in pancreatic Beta-cells. Rev Diabet Stud. 2007;4(1):25-32doi: 10.1900/RDS.2007.4.25.
Shameli, A., Yamanouchi, J., Thiessen, S., & Santamaria, P. (2007). Endoplasmic reticulum stress caused by overexpression of islet-specific glucose-6-phosphatase catalytic subunit-related protein in pancreatic Beta-cells. The review of diabetic studies : RDS, 4(1), 25-32. https://doi.org/10.1900/RDS.2007.4.25
Shameli, Afshin, et al. "Endoplasmic reticulum stress caused by overexpression of islet-specific glucose-6-phosphatase catalytic subunit-related protein in pancreatic Beta-cells." The review of diabetic studies : RDS vol. 4,1 (2007): 25-32. doi: https://doi.org/10.1900/RDS.2007.4.25
Shameli A, Yamanouchi J, Thiessen S, Santamaria P. Endoplasmic reticulum stress caused by overexpression of islet-specific glucose-6-phosphatase catalytic subunit-related protein in pancreatic Beta-cells. Rev Diabet Stud. 2007;4(1):25-32. doi: 10.1900/RDS.2007.4.25. Epub 2007 May 10. PMID: 17565413; PMCID: PMC1892522.
Copy Download .nbib Format: NLM
Bis(quercetinato)oxovanadium IV Reverses Metabolic Changes in Streptozotocin-Induced Diabetic Mice.

The review of diabetic studies : RDS

Shukla R, Padhye S, Modak M, Ghaskadbi SS, Bhonde RR.
PMID: 17565414
Rev Diabet Stud. 2007;4(1):33-43. doi: 10.1900/RDS.2007.4.33. Epub 2007 May 10.

Organic vanadium compounds offer several advantages in the treatment of diabetes, yet they are impractical to use because of known side effects. In order to ameliorate the side effects of vanadium, we conjugated it with quercetin to form bis(quercetinato)oxovanadium...

Cite
Shukla R, Padhye S, Modak M, et al. Bis(quercetinato)oxovanadium IV Reverses Metabolic Changes in Streptozotocin-Induced Diabetic Mice. Rev Diabet Stud. 2007;4(1):33-43doi: 10.1900/RDS.2007.4.33.
Shukla, R., Padhye, S., Modak, M., Ghaskadbi, S. S., & Bhonde, R. R. (2007). Bis(quercetinato)oxovanadium IV Reverses Metabolic Changes in Streptozotocin-Induced Diabetic Mice. The review of diabetic studies : RDS, 4(1), 33-43. https://doi.org/10.1900/RDS.2007.4.33
Shukla, Ruchi, et al. "Bis(quercetinato)oxovanadium IV Reverses Metabolic Changes in Streptozotocin-Induced Diabetic Mice." The review of diabetic studies : RDS vol. 4,1 (2007): 33-43. doi: https://doi.org/10.1900/RDS.2007.4.33
Shukla R, Padhye S, Modak M, Ghaskadbi SS, Bhonde RR. Bis(quercetinato)oxovanadium IV Reverses Metabolic Changes in Streptozotocin-Induced Diabetic Mice. Rev Diabet Stud. 2007;4(1):33-43. doi: 10.1900/RDS.2007.4.33. Epub 2007 May 10. PMID: 17565414; PMCID: PMC1892525.
Copy Download .nbib Format: NLM
Improved Monitoring of the Hyperglycemic State in Type 1 Diabetes Patients by Use of the Glycoalbumin/HbA1c Ratio.

The review of diabetic studies : RDS

Imai T, Oikawa Y, Shimada A.
PMID: 17565415
Rev Diabet Stud. 2007;4(1):44-8. doi: 10.1900/RDS.2007.4.44. Epub 2007 May 10.

AIM: Generally, the level of glycoalbumin (GA) is approximately 3 times higher than that of HbA1c. However, in type 1 diabetic patients, we often find an even higher GA/HbA1c ratio of nearly 3.5. Therefore, this study was performed to...

Cite
Imai T, Oikawa Y, Shimada A. Improved Monitoring of the Hyperglycemic State in Type 1 Diabetes Patients by Use of the Glycoalbumin/HbA1c Ratio. Rev Diabet Stud. 2007;4(1):44-8doi: 10.1900/RDS.2007.4.44.
Imai, T., Oikawa, Y., & Shimada, A. (2007). Improved Monitoring of the Hyperglycemic State in Type 1 Diabetes Patients by Use of the Glycoalbumin/HbA1c Ratio. The review of diabetic studies : RDS, 4(1), 44-8. https://doi.org/10.1900/RDS.2007.4.44
Imai, Takatoshi, et al. "Improved Monitoring of the Hyperglycemic State in Type 1 Diabetes Patients by Use of the Glycoalbumin/HbA1c Ratio." The review of diabetic studies : RDS vol. 4,1 (2007): 44-8. doi: https://doi.org/10.1900/RDS.2007.4.44
Imai T, Oikawa Y, Shimada A. Improved Monitoring of the Hyperglycemic State in Type 1 Diabetes Patients by Use of the Glycoalbumin/HbA1c Ratio. Rev Diabet Stud. 2007;4(1):44-8. doi: 10.1900/RDS.2007.4.44. Epub 2007 May 10. PMID: 17565415; PMCID: PMC1892520.
Copy Download .nbib Format: NLM
C-Peptide in the vessel wall.

The review of diabetic studies : RDS

Walcher D, Marx N.
PMID: 20039007
Rev Diabet Stud. 2009;6(3):180-6. doi: 10.1900/RDS.2009.6.180. Epub 2009 Nov 10.

Patients with insulin resistance and early type 2 diabetes exhibit an increased sensitivity to develop a diffuse and extensive pattern of arteriosclerosis leading to a remarkable increase in vascular complications, including myocardial infarction and stroke. The accelerated atherosclerosis in...

Cite
Walcher D, Marx N. C-Peptide in the vessel wall. Rev Diabet Stud. 2009;6(3):180-6doi: 10.1900/RDS.2009.6.180.
Walcher, D., & Marx, N. (2009). C-Peptide in the vessel wall. The review of diabetic studies : RDS, 6(3), 180-6. https://doi.org/10.1900/RDS.2009.6.180
Walcher, Daniel, and Marx, Nikolaus. "C-Peptide in the vessel wall." The review of diabetic studies : RDS vol. 6,3 (2009): 180-6. doi: https://doi.org/10.1900/RDS.2009.6.180
Walcher D, Marx N. C-Peptide in the vessel wall. Rev Diabet Stud. 2009;6(3):180-6. doi: 10.1900/RDS.2009.6.180. Epub 2009 Nov 10. PMID: 20039007; PMCID: PMC2827270.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 198 entries